Atezolizumab市場：依藥物類別、適應症、配銷通路、最終用戶、地區

預計2023年全球Atezolizumab市場規模為26.8億美元，預計2030年將達78.6億美元，2023年至2030年年複合成長率(CAGR)為16.6%。

圖 1. Atezolizumab全球市場佔有率(%)（依地區），2022 年

Atezolizumab是一種突破性免疫療法藥物，徹底改變了癌症治療。它可以單獨使用或與其他化療藥物合併使用來治療成人某些類型的非小細胞肺癌（NSCLC）。 Atezolizumab注射液屬於一類稱為單株抗體的藥物。這種治療性抗體由羅氏公司開發，可抑製程序性死亡配體 1 (PD-L1) 蛋白，可使癌細胞逃避免疫系統的檢測。透過抑制 PD-L1， Atezolizumab釋放免疫系統辨識和攻擊癌細胞的能力，從而改善患者的預後。 Atezolizumab注射液也與其他化療藥物合併用於治療成人某些類型的小細胞肺癌 (SCLC)、肝細胞癌 (HCC) 和黑色素瘤（一種皮膚癌）。 Atezolizumab也可單獨用於治療成人和 2 歲以上兒童的某些類型的肺泡軟組織肉瘤（肌肉癌、脂肪癌和神經癌）。

市場動態：

由於幾個關鍵因素，Atezolizumab市場正在經歷顯著成長。首先，全球癌症發生率的上升增加了對有效治療方案的需求。 Atezolizumab在多種癌症（包括肺癌、膀胱癌和乳腺癌）中顯示出有希望的結果，擴大了可治療的患者群體。此外，人們對免疫療法益處的認知不斷提高以及對標靶治療的偏好正在進一步推動市場成長。

然而，儘管機會眾多，但也存在著限制市場的因素。 Atezolizumab的高價是一個主要障礙，限制了低收入國家甚至一些新興市場的患者獲得該藥物。此外，新藥核准流程複雜且耗時，為市場准入帶來了課題。此外，替代免疫療法和生物相似藥的出現也可能阻礙市場成長。

不過， Atezolizumab市場未來市場開拓潛力大。諾華、輝瑞、默克、阿斯特捷利康、百時美施貴寶、百濟神州、信達生物、基因泰克和艾伯維等主要企業的研發努力將帶來創新治療方法和進一步的市場擴張。對精準醫療的日益關注和伴同性診斷的發展也為使用Atezolizumab的個體化治療方法創造了機會。

本研究的主要特點

• 本報告對全球Atezolizumab市場進行了詳細分析，包括以2022年為基準年的預測期（2023-2030）的市場規模和複合年成長率。
• 該報告還揭示了各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
• 該報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
• 本研究介紹的全球Atezolizumab市場的主要企業包括羅氏、諾華、輝瑞、默克、阿斯特捷利康、百時美施貴寶、百濟神州、信達生物、基因泰克、艾伯維等。
• 該報告的見解使行銷人員和負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出資訊的決策。
• Atezolizumab全球市場報告面向產業內的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 透過用於分析全球Atezolizumab市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與假設

• 研究目標
• 假設
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

• 市場動態
  • 促進因素
• 全球癌症發生率增加
• 對有效治療方案的需求增加
  • 抑制因素
• Atezolizumab的高成本
  • 機會
• 主要企業持續研發配合措施
• 影響分析
• 主要亮點
• 監管場景
• 產品發布/核准
• PEST分析
• 波特的分析
• 併購場景

第4章全球Atezolizumab市場 -冠狀病毒(COVID-19) 大流行的影響

• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 供需面分析
• 經濟影響

第 5 章 全球Atezolizumab市場，依藥物類別，2018-2030

• 介紹
• PD-L1抑制劑
• PD-1抑制劑
• CTLA-4抑制劑
• 免疫調節劑
• 其他

第6章 全球Atezolizumab市場，依適應症分類，2018-2030 年

• 介紹
• 肺癌
• 膀胱癌
• 黑色素瘤
• 霍奇金淋巴瘤
• 頭頸癌
• 其他

第 7 章全球Atezolizumab市場，依配銷通路分類，2018-2030 年

• 介紹
• 醫院藥房
• 零售藥房
• 線上藥房

第 8 章全球Atezolizumab市場，依最終用戶分類，2018-2030 年

• 介紹
• 醫院
• 居家醫療
• 專科診所
• 其他

第9章全球Atezolizumab市場，依地區，2018-2030年

• 介紹
• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲

第10章競爭形勢

• Roche
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol-Myers Squibb
• BeiGene
• Innovent Biologics
• Genentech
• AbbVie

第11章 章節

• 調查方法
• 關於出版商

The Global Atezolizumab Market size is estimated to be valued at US$ 2.68 billion in 2023 and is expected to reach US$ 7.86 billion by 2030, grow at a compound annual growth rate (CAGR) of 16.6% from 2023 to 2030.

Figure 1. Global Global Atezolizumab Market Share (%), By Region, 2022

Atezolizumab is a breakthrough immunotherapy drug that has revolutionized the treatment of cancer. It can be used alone or with other chemotherapy medications to treat certain types of non-small cell lung cancer (NSCLC) in adults. Atezolizumab injection is in a class of medications called monoclonal antibodies. This therapeutic antibody, developed by Roche, inhibits the programmed death-ligand 1 (PD-L1) protein, which enables cancer cells to evade immune system detection. By blocking PD-L1, atezolizumab unleashes the power of the immune system to recognize and attack cancer cells, leading to improved patient outcomes. Atezolizumab injection is also used in combination with other chemotherapy medications to treat certain types of small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and melanoma (a type of skin cancer) in adults. Atezolizumab is also used alone to treat certain types of alveolar soft tissue sarcomas (cancer that forms in muscles, fat, or nerves) in adults and children 2 years of age or older.

Market Dynamics:

The market for atezolizumab is experiencing significant growth, driven by several key factors. Firstly, the rising incidence of cancer globally is increasing the demand for effective treatment options. Atezolizumab has shown promising results in various cancers, including lung, bladder, and breast cancer, thus expanding the addressable patient population. Additionally, the growing awareness about the benefits of immunotherapy and the preference for targeted therapies are further bolstering market growth.

However, despite the numerous opportunities, there are certain factors restraining the market. The high cost of atezolizumab is a major barrier, limiting access to patients in lower-income countries and even in some developed markets. Additionally, the complex and lengthy regulatory approval process for new drugs poses a challenge for market entry. Moreover, the emergence of alternative immunotherapy treatments and the availability of biosimilars could also hinder market growth.

Nevertheless, the market for atezolizumab holds immense potential for future development. The ongoing research and development efforts by key players such as Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie are expected to yield innovative treatment options, expanding the market further. The increasing focus on precision medicine and the development of companion diagnostics are also creating opportunities for personalized treatment approaches using atezolizumab.

Key Features of the Study:

• This report provides an in-depth analysis of the global atezolizumab market, including market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), with 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• Key players in the global atezolizumab market profiled in this study include Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie
• Insights from this report would enable marketers and management authorities to make informed decisions regarding future product launches, upgrades, market expansion, and marketing tactics.
• The global atezolizumab market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders will have ease in decision-making through various strategy matrices used for analyzing the global atezolizumab market.

Atezolizumab Market Segmentation:

• By Drug Class:
  • PD-L1 Inhibitors
  • PD-1 Inhibitors
  • CTLA-4 Inhibitors
  • Immunomodulators
  • Others
• By Indication:
  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin's Lymphoma
  • Head and Neck Cancer
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End User:
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Top Companies in Atezolizumab Market
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • AstraZeneca
  • Bristol-Myers Squibb
  • BeiGene
  • Innovent Biologics
  • Genentech
  • AbbVie

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Atezolizumab, By Drug Class
  • Market Atezolizumab, By Indication
  • Market Atezolizumab, By Distribution Channel
  • Market Atezolizumab, By End User
  • Market Atezolizumab, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Rising incidence of cancer globally
• Increasing demand for effective treatment options
  • Restraints
• High cost of atezolizumab
  • Opportunities
• Ongoing research and development efforts by key players
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Atezolizumab Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Atezolizumab Market, By Drug Class, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• PD-L1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• PD-1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• CTLA-4 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Immunomodulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Atezolizumab Market, By Indication, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Bladder Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Melanoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Hodgkin's Lymphoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Head and Neck Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Atezolizumab Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Atezolizumab Market, By End User, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Homecare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Atezolizumab Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Country 2019-2030
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)

10. Competitive Landscape

• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
• Pfizer
• Merck
• AstraZeneca
• Bristol-Myers Squibb
• BeiGene
• Innovent Biologics
• Genentech
• AbbVie
• Analyst Views

11. Section

• Research Methodology
• About us